Original Research

Biosimilars for Healthcare Professionals

Author(s):

Read More »

One-day out-patient prescribing patterns including the use of generics at a national referral hospital in Kenya; implications for the future

Author(s): , , , , ,

Background: Poor prescribing habits lead to ineffective and unsafe treatment for patients, exacerbating or prolonging of illness as well as causing distress and harm to them. Drug utilization studies can… Read More »

Bioequivalence Study of Two Formulations of 60 mg Daclatasivir in Healthy Volunteers

Author(s): , , , , ,

Objective: the aim of this study was to assess the bioequivalence between two different formulations of daclatasivir 60 mg film coated tablets through pharmacokinetics comparison. Method: this study was an… Read More »

Building trust on biosimilars: Continuous safety surveillance of a biosimilar Bevacizumab (BEVAX®) in Argentina

Author(s): , , , , ,

Abstract: Introduction and study objectives: The evaluation of the benefit-risk ratio of a drug is essential throughout its whole life cycle to guarantee that therapeutic efficacy for the authorized indications… Read More »

Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2

Published in: Volume 7 / Year 2018 / Issue 2
Author(s): , , , , , ,

Abstract: Background: This analysis evaluates the patient-reported outcomes (PROs) in two randomized studies of biosimilar LY2963016 insulin glargine (LY IGlar) and Lantus® insulin glargine (IGlar), when used in combination with mealtime… Read More »

Page 4 of 4 « Previous1 2 3 4
Go Back Print